<DOC>
	<DOCNO>NCT03060629</DOCNO>
	<brief_summary>The primary purpose study assess preventive vaccine efficacy ( VE ) , safety tolerability heterologous prime/boost regimen utilize Ad26.Mos4.HIV aluminum-phosphate adjuvanted Clade C gp140 prevention Human Immuno Virus ( HIV ) infection HIV-seronegative woman reside sub-Saharan Africa confirm HIV-1 infection diagnose Month 7 Month 24 visit .</brief_summary>
	<brief_title>A Study Assess Efficacy Heterologous Prime/Boost Vaccine Regimen Ad26.Mos4.HIV Aluminum Phosphate-Adjuvanted Clade C gp140 Preventing Human Immunodeficiency Virus ( HIV ) -1 Infection Women Sub-Saharan Africa</brief_title>
	<detailed_description />
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Aluminum phosphate</mesh_term>
	<criteria>Sexually active , define sexual intercourse male partner least twice past 30 day prior screen , consider site staff risk Human Immunodeficiency Virus ( HIV ) infection Access participate HIV Vaccine Trials Network ( HVTN ) Clinical Research Sites ( CRS ) willingness follow plan duration study Willingness discus HIV infection risk willing receive HIV risk reduction counsel appropriate referral minimize HIV acquisition , applicable Negative beta human chorionic gonadotropin ( betaHCG ) pregnancy test perform prior vaccination day initial vaccination . Persons NOT reproductive potential due undergone total hysterectomy bilateral oophorectomy ( verified medical record ) , require undergo pregnancy test Participants must also agree seek pregnancy alternative method , artificial insemination vitro fertilization 3 month last vaccination Investigational research agent receive within 30 day first vaccination HIV vaccine ( ) receive prior HIV vaccine trial . For volunteer receive control/placebo HIV vaccine trial , HVTN 705/HPX2008 ( Protocol Safety Review Team ) PSRT determine eligibility casebycase basis Live attenuate vaccine influenza vaccine receive within 30 day first vaccination schedule within 14 day injection ( example : measles , mumps , rubella [ MMR ] ; oral polio vaccine [ OPV ] ; varicella ; yellow fever ) Influenza vaccine vaccine live attenuate vaccine receive within 14 day prior first vaccination ( eg , tetanus , pneumococcal , Hepatitis A B ) Immunosuppressive medication receive within 6 month first vaccination</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>